Meet the MedCity Media Team

And take 2 minutes to help us make better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

Stock rises for AcelRX as pain management drug device succeeds in late-stage study

8:12 am by | 0 Comments

(Reuters) - AcelRX Pharmaceuticals Inc said its experimental drug device to treat post-operative pain met the main goal of controlling pain in a late-stage study among patients who had undergone knee or hip replacement surgery.

Shares of the company rose 31 percent to $8.44 in trading before the bell.

The device showed that the drug showed a decrease in pain intensity as measured on a clinical scale, compared to a placebo.

The study is the last of the three late-stage trials of the Sufentanil NanoTab PCA System, which allows patients to dose themselves with painkiller tablets.


The therapy had shown in the two earlier late-stage trials that it was at least as effective as the standard of care in treating post-operative pain and was significantly better than a placebo.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.